Apalutamide Study Again Demonstrates the Advantages of Nanoforming Over Traditional Cancer Treatment Formulations
Press Release
Nanoform Finland Plc
February 29, 2024
08:11 a.m. Finnish time / 07:11 a.m. Swedish time
Apalutamide Study Again Demonstrates the Advantages of Nanoforming Over Traditional Cancer Treatment Formulations
Helsinki, Finland – February 29, 2024 – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, today announced it had received positive results from its own pre-clinical, in-vivo study of a nanocrystalline-enabled apalutamide oral formulation, which shows potential to enable a much smaller tablet than Erleada® [1], a nonsteroidal antiandrogen (NSAA) blockbuster amorphous solid dispersion (ASD) medicine used to treat prostate cancer.
The nanocrystalline-enabled formulation provided high serum concentration (Cmax), fast time to peak drug concentration (Tmax), and 100% absolute bioavailability. This study was conducted in order to provide further validation of nanocrystalline formulations as effective alternatives to amorphous solid dispersions.
“These encouraging results follow our successful clinical study on nanoenzalutamide, our improved version of yet another blockbuster ASD product in the prostate cancer field, and further validates the opportunity to leverage our formulation platforms to help patients by transitioning to nanoformed products,” said Dr. Edward Haeggström, CEO of Nanoform. “Through our proprietary AI technology platform, we’ve identified that most ASD products are amenable for improvements with Nanoform technologies, covering multiple therapy areas including cancer, HIV and CNS.”
ASDs are used to enable poorly soluble drugs, and there are over 50 such products on the global market worth +$50 billion in annual sales, and hundreds more in development. ASDs require a high polymer content leading to reduced drug loading and large or many tablets, presenting a challenge for many patient populations, as well as cost, manufacturing and environment.
Nanoform’s nanocrystalline formulations enable significantly higher drug loading, allowing for smaller pills and a reduced pill burden. Its technology is free from organic hydrocarbon solvents, offering an environmentally sustainable alternative. Nanoform intends to conduct more similar studies on other APIs. The company was recently granted match funding of 4.3m Euros from Business Finland towards creating formulation platforms around four key drug delivery areas of oral, inhaled, long acting injectables and high drug load subcutaneous biologics.
Nanoform’s technology delivers some of the world’s smallest nanoparticles at clinical and commercial scale. Used by multiple pharmaceutical innovator partners, it is suitable for new product developments, lifecycle management through improved reformulations, and differentiated generics across oral, hydrogel, ophthalmic, inhalable, and injectable dose forms. Nanoform’s state-of-the-art development and manufacturing facility is in Helsinki, Finland.
[1] Erleada is a registered trademark for Apalutamide owned by Johnson & Johnson / Janssen Biotech, Inc.
For further information, please contact:
Christian Jones, Chief Commercial Officer
Nanoform Finland Plc
+44 7804 474 771
Investors, financial- and general media, please contact:
Henri von Haartman, Director of Investor Relations
Nanoform Finland Plc
+46 7686 650 11
Pharmaceutical media, please contact:
Chris Halling, Director of Communications
Orientation Marketing
+44 (0)7580 041073
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit www.nanoform.com.
Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. The words “may”, “will”, “could”, “would”, “should”, “expect”, “plan”, “anticipate”, “intend”, believe”, “estimate”, “predict”, “project”, “potential”, “continue”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform’s business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2023 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
